| Q35317749 | Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients |
| Q41995310 | Autoactivation of the Epstein-Barr virus oncogenic protein LMP1 during type II latency through opposite roles of the NF-kappaB and JNK signaling pathways |
| Q37154847 | Epstein-Barr virus in systemic autoimmune diseases |
| Q35115666 | Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines. |
| Q33772245 | Herpesvirus saimiri |
| Q41314439 | How Viruses Contribute to the Pathogenesis of Hemophagocytic Lymphohistiocytosis |
| Q39683879 | Human monocytic cell lines transformed in vitro by Epstein-Barr virus display a type II latency and LMP-1-dependent proliferation |
| Q36784009 | Impaired Cytokine Responses to Epstein-Barr Virus Antigens in Systemic Lupus Erythematosus Patients |
| Q39410061 | Inhibition of latent membrane protein 1 impairs the growth and tumorigenesis of latency II Epstein-Barr virus-transformed T cells. |
| Q34699997 | LMP1-induced cell death may contribute to the emergency of its oncogenic property. |
| Q34478829 | Reduced response to Epstein-Barr virus antigens by T-cells in systemic lupus erythematosus patients. |
| Q38998165 | Role of latent membrane protein 1 in chronic active Epstein-Barr virus infection-derived T/NK-cell proliferation |